Skip to main content
Top
Published in: Breast Cancer Research 1/2002

01-07-2002 | Meeting abstract

Technology update

Author: KC Young

Published in: Breast Cancer Research | Special Issue 1/2002

Login to get access

Excerpt

Full field digital mammography has continued to develop. There is now a remarkable variety of different designs. One of the oldest (photo-stimulable phosphors) has received a new lease of life with the introduction of dual reading technology at a 50 m resolution. Systems using a selenium detector plate with a 70 m resolution are being introduced this year. Such systems have the advantage of converting X-ray energy directly to an electrical signal. A low dose system, which uses a scanning technique with a linear array of silicon detectors, has also been developed. Dual displays with 2000×2500 resolution are becoming standard. While such systems may be readily introduced into a symptomatic role, their use in screening remains problematic. All the digital systems can overcome the latitude limitations of the traditional film screen mammography, and appear to offer advantages in terms of image quality, particularly with better contrast resolution. The overall contrast can also be optimised for each image. The main limitations to the wider use of this technology remain the high start-up costs and the lack of proven clinical advantages. …
Metadata
Title
Technology update
Author
KC Young
Publication date
01-07-2002
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 1/2002
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr508

Other articles of this Special Issue 1/2002

Breast Cancer Research 1/2002 Go to the issue

Meeting abstract

Imaging implants

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine